

1. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis and rheumatism*. 1984;27(4):361-8.
2. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Annals of the rheumatic diseases*. 2009;68(6):777-83.
3. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. *Annals of the rheumatic diseases*. 2009;68 Suppl 2:ii1-44.
4. Sociedad Española de Reumatología. ESPOGUÍA: guía de práctica clínica sobre el manejo de los pacientes con Espondiloartritis. [[monografía en internet]]. Madrid: Sociedad Española de Reumatología; 2009 [updated [20 septiembre 2013]].
5. Catanoso M, Pipitone N, Salvarani C. Epidemiology of psoriatic arthritis. *Reumatismo*. 2012;64(2):66-70.
6. Guías de Práctica Clínica. Guíasalud.es. Fecha de consulta: 2015 Marzo 10. Disponible en: <http://www.guiasalud.es/web/guest/guias-practica-clinica>.
7. Akkoc N, Khan MA. Ankylosing Spondylitis and the Spondyloarthropathies. In: Weissman R, Heijden vd, eds, editor. *Epidemiology of Ankylosing Spondylitis and related Spondyloarthropathies*: Philadelphia Mosby Elsevier; 2006. p. 117-31.
8. Munoz-Fernandez S, de Miguel E, Cobo-Ibanez T, Carmona L, Steiner M, Descalzo MA, et al. Early spondyloarthritis: results from the pilot registry ESPIDEP. *Clinical and experimental rheumatology*. 2010;28(4):498-503.
9. Stolwijk C, Boonen A, van Tubergen A, Reveille JD. Epidemiology of spondyloarthritis. *Rheumatic diseases clinics of North America*. 2012;38(3):441-76.
10. Collantes E, Veroz R, Escudero A, Munoz E, Munoz MC, Cignal A, et al. Can some cases of 'possible' spondyloarthropathy be classified as 'definite' or 'undifferentiated' spondyloarthropathy? Value of criteria for spondyloarthropathies. Spanish Spondyloarthropathy Study Group. *Joint, bone, spine : revue du rhumatisme*. 2000;67(6):516-20.
11. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. *Rheumatology (Oxford, England)*. 2014;53(4):650-7.
12. Fernandez Sueiro JL, Juanola Roura X, Canete Crespillo Jde D, Torre Alonso JC, Garcia de Vicuna R, Queiro Silva R, et al. Documento SER de consenso sobre el uso de terapias biológicas en la artritis psoriásica. *Reumatologia clinica*. 2011;7(3):179-88.
13. Juanola Roura X, Zarco Montejo P, Sanz Sanz J, Munoz Fernandez S, Mulero Mendoza J, Linares Ferrando LF, et al. [Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis]. *Reumatologia clinica*. 2011;7(2):113-23.
14. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. *Arthritis Rheum*. 1998;41(1):58-67.
15. Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. *Annals of the rheumatic diseases*. 2001;60(11):1040-5.
16. O'Neill T, Silman AJ. Psoriatic arthritis. Historical background and epidemiology. *Baillieres Clin Rheumatol*. 1994;8(2):245-61.

17. Gonzalez-Alvaro I, Martinez-Fernandez C, Dorantes-Calderon B, Garcia-Vicuna R, Hernandez-Cruz B, Herrero-Ambrosio A, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. *Rheumatology (Oxford, England)*. 2014.
18. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. *Clin Exp Rheumatol*. 2002;20(6 Suppl 28):S16-22.
19. Carmona L, Gonzalez-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. *Annals of the rheumatic diseases*. 2003;62(9):897-900.
20. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. *Arthritis Rheum*. 1998;41(6):1103-10.
21. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. *Annals of the rheumatic diseases*. 1993;52(3):174-6.
22. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. *Clin Exp Rheumatol*. 2008;26(5 Suppl 51):S35-61.
23. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. *Arthritis Rheum*. 1997;40(10):1868-72.
24. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. *Annals of the rheumatic diseases*. 2011;70(11):1921-5.
25. Estrategia en enfermedades reumáticas y musculoesqueléticas del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2013.
26. Abasolo Alcázar L, Gratacós Masmitjà J, Hidalgo Vega A, Jover Jover J, Lizán Tudela L, Paz Ruiz S, et al. Costes y cargas de las enfermedades reumáticas. *Science Communications*. Springer SBM Spain, S.A.U. Madrid.
27. Gratacos J, Dauden E, Gomez-Reino J, Moreno JC, Casado MA, Rodriguez-Valverde V. Health-related quality of life in psoriatic arthritis patients in Spain. *Reumatologia clinica*. 2014;10(1):25-31.
28. Loza E, Abasolo L, Jover JA, Carmona L. Burden of disease across chronic diseases: a health survey that measured prevalence, function, and quality of life. *The Journal of rheumatology*. 2008;35(1):159-65.
29. Pereira J, Cañón J, Álvarez E, Gènova R. La medida de los problemas de salud en el ámbito internacional: los estudios de carga de enfermedad. *Rev Admin Sanitaria*. 2001;V(19):441-66.
30. Ariza-Ariza R, Hernandez-Cruz B, Collantes E, Batlle E, Fernandez-Sueiro JL, Gratacos J, et al. Work disability in patients with ankylosing spondylitis. *J Rheumatol*. 2009;36(11):2512-6.
31. Lajas C, Abasolo L, Bellajdel B, Hernandez-Garcia C, Carmona L, Vargas E, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. *Arthritis Rheum*. 2003;49(1):64-70.
32. Boonen A. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. *Nature clinical practice Rheumatology*. 2006;2(10):546-53.
33. Lázaro P, Parody E, Méndez Rubio J, Alfaro N. También está en tu mano. Impacto de las enfermedades reumáticas en España. Un análisis de técnicas avanzadas de investigación en Servicios de Salud (TAISS) para la Fundación Abbot.2009.
34. Petrikova A, Dolezal T, Klimes J, Vocelka M, Sedova L, Kolar J. The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008. *Rheumatology international*. 2013;33(7):1813-9.

35. Pentek M, Poor G, Wiland P, Olejarova M, Brzosko M, Codreanu C, et al. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. *The European journal of health economics : HEPAC : health economics in prevention and care*. 2014;15 Suppl 1:S35-43.
36. Palla I, Trieste L, Tani C, Talarico R, Cortesi PA, Mosca M, et al. A systematic literature review of the economic impact of ankylosing spondylitis. *Clin Exp Rheumatol*. 2012;30 (4 Suppl. 73):S136–S41.
37. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. *Annals of the rheumatic diseases*. 2006;65(9):1175-83.
38. Brodszky V, Balint P, Geher P, Hodinka L, Horvath G, Koo E, et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. *Rheumatology international*. 2009;30(2):199-205.
39. Kobelt G, Sobocki P, Mulero J, Gratacos J, Pocovi A, Collantes-Estevez E. The burden of ankylosing spondylitis in Spain. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2008;11(3):408-15.
40. Collantes E. Espondiloartropatías. Concepto, Clasificación y Características Generales. In: Pascual E, Rodriguez V, Carbonell J, Gómez-Reino J, editors. *Tratado de reumatología: ARAN Ediciones Madrid (España)*; 1998.
41. van der Linden S; van der Heijde D. Classification of spondyloarthropathies. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt M, Weissman MH, editors. *Reumatology: Edinburgh: Mosby (Elsevier)*; 2003. p. 1149-51.
42. Braun J, Sieper J. Ankylosing spondylitis. *Lancet*. 2007;369(9570):1379-90.
43. Khan MA. Thoughts concerning the early diagnosis of ankylosing spondylitis and related diseases. *Clinical and experimental rheumatology*. 2002;20(6 Suppl 28):S6-10.
44. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. *Annals of the rheumatic diseases*. 2015;74(1):65-73.
45. van der Horst-Bruinsma IE, Nurmohamed MT, Landewe RB. Comorbidities in patients with spondyloarthritis. *Rheumatic diseases clinics of North America*. 2012;38(3):523-38.
46. Mercieca C, van der Horst-Bruinsma IE, Borg AA. Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice. *Current rheumatology reports*. 2014;16(8):434.
47. Cauli A, Mathieu A. Psoriatic arthritis: genetics and pathogenesis. *Reumatismo*. 2012;64(2):71-8.
48. Gladman DD, Farewell VT. HLA studies in psoriatic arthritis: current situation and future needs. *The Journal of rheumatology*. 2003;30(1):4-6.
49. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. *Arthritis and rheumatism*. 2009;61(2):233-9.
50. Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. *The Journal of rheumatology*. 2008;35(5):877-82.
51. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. *Arthritis and rheumatism*. 2008;59(9):1322-31.
52. Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. *Annals of the rheumatic diseases*. 2000;59(11):904-9.

53. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. *Rheumatology (Oxford, England)*. 2008;47(5):718-23.
54. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. *Archives of dermatological research*. 2006;298(7):321-8.
55. Cinar M, Dinc A, Simsek I, Erdem H, Koc B, Pay S, et al. Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study. *Rheumatology international*. 2010;30(3):331-40.
56. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. *Arthritis and rheumatism*. 2008;58(7):1981-91.
57. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford, England)*. 2010;49(3):563-70.
58. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. *Annals of the rheumatic diseases*. 2004;63(6):665-70.
59. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. *Annals of the rheumatic diseases*. 2008;67(9):1276-81.
60. Weiss A, Song IH, Haibel H, Listing J, Sieper J. Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. *Arthritis research & therapy*. 2014;16(1):R35.
61. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. *Arthritis and rheumatism*. 2006;55(6):864-72.
62. Kyburz D, Gabay C, Michel BA, Finckh A. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. *Rheumatology (Oxford, England)*. 2011;50(6):1106-10.
63. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. *Rheumatology (Oxford, England)*. 2004;43(7):906-14.
64. van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW, et al. Long-term impact of delay in assessment of patients with early arthritis. *Arthritis and rheumatism*. 2010;62(12):3537-46.
65. van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. *Annals of the rheumatic diseases*. 2015;74(5):806-12.
66. Collantes E, Zarco P, Munoz E, Juanola X, Mulero J, Fernandez-Sueiro JL, et al. Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. *Rheumatology (Oxford, England)*. 2007;46(8):1309-15.
67. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Annals of the rheumatic diseases*. 2013;72(6):815-22.

68. Juanola Roura X, Collantes Estevez E, Leon Vazquez F, Torres Villamor A, Garcia Yebenes MJ, Queiro Silva R, et al. Recommendations for the detection, study and referral of inflammatory low-back pain in primary care. *Reumatologia clinica*. 2015;11(2):90-8.
69. Ash ZR, Barkham N, McGonagle D, Hensor E, Emery P, Marzo-Ortega H. Long term results of a remission induction approach to early axial spondyloarthritis: Still looking for the window of opportunity. *Arthritis and rheumatism*. 2011;63(10).
70. Baraliakos X, Koenig A, Jones H, Szumski A, Collier D, Bananis E. AB0861 Relationship between disease duration and treatment response in patients with ankylosing spondylitis (AS). *Annals of the rheumatic diseases*. 2013;71(Suppl 3):687.
71. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. *Annals of the rheumatic diseases*. 2012;71(3):319-26.
72. Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. *Arthritis and rheumatism*. 2009;60(4):946-54.
73. Callhoff J, Sieper J, Weiss A, Zink A, Listing J. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. *Annals of the rheumatic diseases*. 2014.
74. Dougados M, Van Der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: A multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis and Rheumatology*. 2014;66(8):2091-102.
75. Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. *Annals of the rheumatic diseases*. 2014;73(1):39-47.
76. Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, et al. A Randomized, Double-blind, Placebo-controlled, 16-Week Study of Subcutaneous Golimumab in Patients With Active Non-radiographic Axial Spondyloarthritis. *Arthritis & rheumatology*. 2015;67(10):2702-12.
77. Lekpa FK, Poulain C, Wendling D, Soubrier M, De Bandt M, Berthelot JM, et al. Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. *Arthritis research & therapy*. 2012;14(2):R53.
78. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Annals of the rheumatic diseases*. 2009;68(6):770-6.
79. Dougados M, d'Agostino MA, Benessiano J, Berenbaum F, Breban M, Claudepierre P, et al. The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. *Joint, bone, spine : revue du rhumatisme*. 2011;78(6):598-603.
80. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? *Arthritis care & research*. 2012;64(9):1415-22.

81. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. *Arthritis and rheumatism*. 2009;60(3):717-27.
82. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? *Arthritis and rheumatism*. 2005;52(4):1000-8.
83. van den Berg R, de Hooze M, van Gaalen F, Reijnen M, Huizinga T, van der Heijde D. Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort. *Rheumatology (Oxford, England)*. 2013;52(8):1492-9.
84. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. *Annals of the rheumatic diseases*. 2011;70(6):905-8.
85. Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. *Rheumatology (Oxford, England)*. 2010;49(7):1317-25.
86. Machado MA, Barbosa MM, Almeida AM, de Araujo VE, Kakehasi AM, Andrade EI, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. *Rheumatology international*. 2013;33(9):2199-213.
87. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. *Annals of the rheumatic diseases*. 2014;73(4):710-5.
88. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. *Arthritis and rheumatism*. 2013;65(10):2645-54.
89. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2013;382(9906):1705-13.
90. Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). *Annals of the rheumatic diseases*. 2014;73(5):817-23.
91. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. *Arthritis and rheumatism*. 1991;34(10):1218-27.
92. De La Mata J, Maese J, Martinez JA, Rosario P, Loza E. Current evidence of the management of undifferentiated spondyloarthritis: a systematic literature review. *Seminars in arthritis and rheumatism*. 2011;40(5):421-9, 9.e1-3.
93. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. *Jama*. 1977;237(24):2613-4.
94. Sieper J, Landewe R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. *Arthritis & rheumatology (Hoboken, NJ)*. 2015;67(3):668-77.
95. Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Annals of the rheumatic diseases*. 2011;70(1):25-31.

96. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. *Arthritis research & therapy*. 2005;7(3):R439-44.
97. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. *Arthritis and rheumatism*. 2003;48(6):1667-75.
98. Deng X, Zhang J, Zhang J, Huang F. Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. *Rheumatology international*. 2013;33(6):1409-13.
99. Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J. Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. *Arthritis and rheumatism*. 2013;65(8):2211-3.
00. Song IH, Althoff CE, Haibel H, Hermann KG, Poddubnyy D, Listing J, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. *Annals of the rheumatic diseases* [Internet]. 2012; 71(7):[1212-5 pp.]. Available from: <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/794/CN-00880794/frame.html>.
01. Borrás-Blasco J, Gracia-Perez A, Rosique-Robles JD, Castera ME, Abad FJ. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients. *Expert Opinion on Biological Therapy*. 2014;14(2):145-50.
02. Cantini F, Niccoli L, Cassara E, Kaloudi O, Nannini C. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: A randomized, prospective, long-term, follow-up study. *Biologics: Targets and Therapy* [Internet]. 2013; 7(1):[1-6 pp.]. Available from: <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/769/CN-00912769/frame.html>.
03. De Stefano R, Frati E, De Quattro D, Menza L, Manganelli S. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. *Clinical rheumatology*. 2014;33(5):707-11.
04. Lee J, Noh JW, Hwang JW, Oh JM, Kim H, Ahn JK, et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. *Clinical rheumatology*. 2010;29(10):1149-54.
05. Morck B, Pullerits R, Geijer M, Bremell T, Forsblad-D'Elia H. Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: A two-year pilot study. *Mediators of Inflammation*. 2013;2013.
06. Navarro-Compan V, Moreira V, Ariza-Ariza R, Hernandez-Cruz B, Vargas-Lebron C, Navarro-Sarabia F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. *Clinical rheumatology*. 2011;30(7):993-6.
07. Paccou J, Bacle-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo RM. Dosage adjustment of anti-tumor necrosis factor-alpha inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. *The Journal of rheumatology*. 2012;39(7):1418-23.
08. Zavada J, Uher M, Sisol K, Forejtova S, Jarosova K, Mann H, et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: A propensity score-matched cohort study. *Annals of the rheumatic diseases*. 2014.
09. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. *Arthritis and rheumatism*. 2011;63(6):1543-51.
10. Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. *Annals of the rheumatic diseases*. 2010;69(1):226-9.

11. Zochling J, Maxwell L, Beardmore J, Boonen A. TNF-alpha inhibitors for ankylosing spondylitis. *Cochrane Database of Systematic Reviews* [Internet]. 2005; (3). Available from: <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005468/abstract>.
12. O'Dwyer T, O'Shea F, Wilson F. Exercise therapy for spondyloarthritis: a systematic review. *Rheumatology international*. 2014;34(7):887-902.
13. Giannotti E, Trainito S, Arioli G, Rucco V, Masiero S. Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era. *Clinical rheumatology*. 2014;33(9):1217-30.
14. Laskowski ER, Lexell J. Exercise and sports for health promotion, disease, and disability. *Physical Medicine & Rehabilitation* 2012;4(11):795-6.
15. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Annals of the rheumatic diseases*. 2011;70(6):896-904.
16. Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, Minson CT, Nigg CR, Salem GJ, et al. American College of Sports Medicine position stand. Exercise and physical activity for older adults. *Medicine and science in sports and exercise*. 2009;41(7):1510-30.
17. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. *The Cochrane database of systematic reviews*. 2008(1):Cd002822.
18. Uhrin Z, Kuzis S, Ward MM. Exercise and changes in health status in patients with ankylosing spondylitis. *Archives of internal medicine*. 2000;160(19):2969-75.
19. Cooksey R, Brophy S, Husain MJ, Irvine E, Davies H, Siebert S. The information needs of people living with ankylosing spondylitis: a questionnaire survey. *BMC musculoskeletal disorders*. 2012;13:243.
20. Papagoras C, Markatseli TE, Saougou I, Alamanos Y, Zikou AK, Voulgari PV, et al. Cardiovascular risk profile in patients with spondyloarthritis. *Joint, bone, spine : revue du rhumatisme*. 2014;81(1):57-63.
21. Passalent LA, Soever LJ, O'Shea FD, Inman RD. Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. *The Journal of rheumatology*. 2010;37(4):835-41.
22. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. *Arthritis and rheumatism*. 2012;64(5):1388-98.
23. Chung HY, Machado P, van der Heijde D, D'Agostino MA, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. *Annals of the rheumatic diseases*. 2012;71(6):809-16.
24. Matthey DL, Dawson SR, Healey EL, Packham JC. Relationship between smoking and patient-reported measures of disease outcome in ankylosing spondylitis. *The Journal of rheumatology*. 2011;38(12):2608-15.
25. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. *The Journal of rheumatology*. 2002;29(7):1420-5.
26. Kaan U, Ferda O. Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. *Rheumatology international*. 2005;25(5):357-60.
27. Reed MD, Dharmage S, Boers A, Martin BJ, Buchanan RR, Schachna L. Ankylosing spondylitis: an Australian experience. *Internal medicine journal*. 2008;38(5):321-7.
28. Ward MM, Weisman MH, Davis JC, Jr., Reveille JD. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. *Arthritis and rheumatism*. 2005;53(5):710-7.



29. Aaverns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT. Smoking and outcome in ankylosing spondylitis. *Scandinavian journal of rheumatology*. 1996;25(3):138-42.
30. Fallahi S, Jamshidi AR, Gharibdoost F, Mahmoudi M, Ahmadzadeh N, Nicknam MH. The correlation between pack-years of smoking and disease activity, quality of life, spinal mobility, and sacroiliitis grading in patients with ankylosing spondylitis. *Turkish Journal of Rheumatology*. 2013;28(3):181-8.
31. Bodur H, Ataman S, Rezvani A, Bugdayci DS, Cevik R, Birtane M, et al. Quality of life and related variables in patients with ankylosing spondylitis. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2011;20(4):543-9.
32. Ward MM, Hendrey MR, Malley JD, Learch TJ, Davis JC, Jr., Reveille JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. *Arthritis and rheumatism*. 2009;61(7):859-66.
33. Chen CH, Chen HA, Lu CL, Liao HT, Liu CH, Tsai CY, et al. Association of cigarette smoking with Chinese ankylosing spondylitis patients in Taiwan: a poor disease outcome in systemic inflammation, functional ability, and physical mobility. *Clinical rheumatology*. 2013;32(5):659-63.
34. Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? *Annals of the rheumatic diseases*. 2011;70(12):2152-4.
35. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. *Annals of the rheumatic diseases*. 2015;74(6):1045-50.
36. Kirkham B, de Vlam K, Li W, Boggs R, Mallbris L, Nab HW, et al. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. *Clinical and experimental rheumatology*. 2015;33(1):11-9.
37. Scarpa R, Atteno M, Lubrano E, Provenzano G, D'Angelo S, Spadaro A, et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. *Clinical rheumatology*. 2011;30(8):1063-7.
38. Scarpa R, Peluso R, Atteno M, Manguso F, Spano A, Iervolino S, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. *Clinical rheumatology*. 2008;27(7):823-6.
39. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. *BMJ (Clinical research ed)*. 2010;340:c147.
40. Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). *Annals of the rheumatic diseases*. 2014;73(2):407-13.
41. Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O, et al. Qualifying unmet needs and improving standards of care in psoriatic arthritis. *Arthritis care & research*. 2014;66(12):1759-66.
42. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. *Rheumatology (Oxford, England)*. 2003;42(6):778-83.
43. Coates LC, Moverly AR, McParland L, Brown S, Collier H, al; LJe. Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome. *Arthritis & Rheumatism*. 2013;65(S10):S346.

44. Coates LC, Navarro-Coy N, Brown SR, Brown S, McParland L, Collier H, et al. The TICOPA protocol (Tight COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. *BMC musculoskeletal disorders*. 2013;14:101.
45. Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. *Annals of the rheumatic diseases*. 2014;73(6):1000-6.
46. Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger GG, Gladman DD, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. *Arthritis and rheumatism*. 2012;64(8):2504-17.
47. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet*. 2013;382(9894):780-9.
48. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. *Annals of the rheumatic diseases*. 2014;73(6):990-9.
49. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015.
50. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. *The New England journal of medicine*. 2015;373(14):1329-39.
51. Acosta Felquer ML, Coates LC, Soriano ER, Ranza R, Espinoza LR, Helliwell PS, et al. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. *The Journal of rheumatology*. 2014;41(11):2277-85.
52. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. *Rheumatology (Oxford, England) [Internet]*. 2012; 51(8): [1368-77 pp.]. Available from: <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/669/CN-00842669/frame.html>.
53. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. *The Journal of rheumatology*. 2008;35(3):469-71.
54. Behrens F, Finkenwirth C, Pavelka K, Stolfa J, Sipek-Dolnicar A, Thaci D, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. *Arthritis care & research*. 2013;65(3):464-70.
55. Asaduzzaman ATM, Sikder A, Mahmud MM, Paul HK, Islam MN. Efficacy and safety of leflunomide in psoriatic arthritis. *Journal of Pakistan Association of Dermatologists [Internet]*. 2014; 24(1):[51-6 pp.]. Available from: <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/967/CN-00988967/frame.html>.
56. Asiri A, Thavaneswaran A, Kalman-Lamb G, Chandran V, Gladman DD. The effectiveness of leflunomide in psoriatic arthritis. *Clinical and experimental rheumatology*. 2014;32(5):728-31.
57. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. *Annals of the rheumatic diseases*. 2012;71(1):4-12.

58. Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. *Clinical and experimental rheumatology*. 2010;28(5 Suppl 61):S132-7.
59. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. *J Am Acad Dermatol*. 2008;58(5):851-64.
60. Luelmo J, Gratacos J, Moreno Martinez-Losa M, Ribera M, Romani J, Calvet J, et al. A report of 4 years of experience of a multidisciplinary unit of psoriasis and psoriatic arthritis. *Reumatologia clinica*. 2014;10(3):141-6.
61. Mease P. Methotrexate in psoriatic arthritis. *Bulletin of the Hospital for Joint Disease (2013)*. 2013;71 Suppl 1:S41-5.
62. Fernandez Sueiro JL, Juanola Roura X, Canete Crespillo Jde D, Torre Alonso JC, Garcia de Vicuna R, Queiro Silva R, et al. [Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis]. *Reumatologia clinica*. 2011;7(3):179-88.
63. Pereda CA, Nishishinya MB, Martinez Lopez JA, Carmona L. Efficacy and safety of DMARDs in psoriatic arthritis: a systematic review. *Clinical and experimental rheumatology*. 2012;30(2):282-9.
64. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. *Annals of the rheumatic diseases*. 2008;67(6):855-9.
65. Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O'Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. *Lancet*. 2015.
66. Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis and rheumatism*. 2012;64(10):3156-67.
67. Behrens F, Canete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. *Rheumatology (Oxford, England)*. 2015;54(5):915-26.
68. Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, Van Der Heijde D, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). *Annals of the rheumatic diseases*. 2014;73(9):1689-94.
69. Kavanaugh A, McInnes IB, Mease PJ, Krueger GG, Gladman DD, Van Der Heijde D, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. *Annals of the rheumatic diseases*. 2013;72(11):1777-85.
70. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rodevand E, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. *Annals of the rheumatic diseases*. 2014;73(1):132-7.
71. Glintborg B, Ostergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. *Arthritis and rheumatism*. 2011;63(2):382-90.
72. Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. *Annals of the rheumatic diseases*. 2008;67(3):364-9.

73. Lopez-Ferrer A, Laiz-Alonso A. Psoriatic arthritis: an update. *Actas dermo-sifiliograficas*. 2014;105(10):913-22.
74. Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. *The British journal of dermatology*. 2012;167(3):649-57.
75. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). *Annals of the rheumatic diseases*. 2009;68(5):702-9.
76. Velez NF, Wei-Passanese EX, Husni ME, Mody EA, Qureshi AA. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. *Archives of dermatological research*. 2012;304(1):7-13.
77. Perez-Barrio S, Galindez E, Alzaga JMC, Garcia-Vivar ML, Urigoitia P, Belloso RI. Psoriasis and psoriatic arthropathy multidisciplinary clinic at Basurto University Hospital: 2 years of experience. *Journal of the American Academy of Dermatology*. 2014;70(5):AB180.
78. Foulkes A, Chinoy H, Warren RB. High degree of patient satisfaction and exceptional feedback in a specialist combined dermatology and rheumatology clinic. *British Journal of Dermatology*. 2012;167:38.
79. Van de Kerhof P. Psoriasis. In: Bologna JL, Jorizzo JL, RP R, editors. *Dermatología Madrid: Mosby Elsevier (España)*; 2004. p. 125-49.
80. Grønning K, Skomsvoll JF, Rannestad T, Steinsbekk A. The effect of an educational programme consisting of group and individual arthritis education for patients with polyarthritis—A randomised controlled trial. *Patient Education & Counseling*. 2012;88(1):113-20.
81. Grønning K, Rannestad T, Skomsvoll JF, Rygg LØ, Steinsbekk A. Long-term effects of a nurse-led group and individual patient education programme for patients with chronic inflammatory polyarthritis – a randomised controlled trial. *Journal of Clinical Nursing*. 2014;23(7/8):1005-17.
82. Koksvik HS, Hagen KB, Rodevand E, Mowinckel P, Kvien TK, Zangi HA. Patient satisfaction with nursing consultations in a rheumatology outpatient clinic: A 21-month randomised controlled trial in patients with inflammatory arthritides. *Annals of the rheumatic diseases* [Internet]. 2013; 72(6):[836-43 pp.]. Available from: <http://onlinelibrary.wiley.com/doi/10.1111/acr.12111>
83. Naranjo A, Bilbao A, Erausquin C, Ojeda S, Francisco FM, Rua-Figueroa I, et al. Results of a specific smoking cessation program for patients with arthritis in a rheumatology clinic. *Rheumatology international*. 2014;34(1):93-9.
84. Garcia-Diaz S, Girabent-Farres M, Roig-Vilaseca D, Reina D, Cerda D, Gonzalez M, et al. [Preference for etanercept pen versus syringe in patients with chronic arthritis. Nurse education workshop]. *Enfermeria clinica*. 2013;23(4):164-9.
85. Hennell S, Spark E, Wood B, George E. An evaluation of nurse-led rheumatology telephone clinics. *Musculoskeletal care*. 2005;3(4):233-40.
86. Rudd RE, Blanch DC, Gall V, Chibnik LB, Wright EA, Reichmann W, et al. A randomized controlled trial of an intervention to reduce low literacy barriers in inflammatory arthritis management. *Patient education and counseling*. 2009;75(3):334-9.
87. Homer D, Nightingale P, Jobanputra P. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. *Musculoskeletal care*. 2009;7(2):78-92.
88. Alonso Ruiz A, Vidal Fuentes J, Tornero Molina J, Carbonell Abello J, Lazaro P, Mercado D, et al. [Asistencia quality standards in rheumatology.]. *Reumatologia clinica*. 2007;3(5):218-25.

89. Gomez Reino J, Loza E, Andreu JL, Balsa A, Batlle E, Canete JD, et al. [Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients]. *Reumatologia clinica*. 2011;7(5):284-98.
90. Kalyoncu U, Nakas D, Hayran M, Gossec L, Karadag O, Akdogan A, et al. Nurse-guided completion of the BASDAI questionnaire in ankylosing spondylitis patients with low literacy. *Journal for Nurse Practitioners*. 2010;6(3):201-5.
91. van Eijk-Hustings Y, van Tubergen A, Bostrom C, Braychenko E, Buss B, Felix J, et al. EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. *Annals of the rheumatic diseases*. 2012;71(1):13-9.
92. Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. *Rheumatology (Oxford, England)*. 2010;49(11):2154-64.
93. Katchamart W, Bombardier C. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis. *The Journal of rheumatology*. 2010;37(7):1411-5.
94. de la Torre J, Escandón Peláez S, Fernández Ogando E, García Alonso J, Lozano Mateos M, Perez Ayuso P. Documento de consenso sobre el manejo, administración y monitorización a pacientes en tratamiento con Infliximab®. *Metas de Enfermería*. 2007;. 10: 50-5.
95. Almodovar R, Fernandez Nebro A, Gracia Perez LA, Román Ivorra JA, Rodríguez Cros JR, del Pino Montes J, et al. AB1165 Effectiveness of Nursing Consultations in Rheumatology: Results from the Score Study. *Annals of the rheumatic diseases*. 2015;74(Suppl 2):1292.
96. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Annals of the rheumatic diseases*. 2010;69(4):631-7.
97. Larsson I, Arvidsson S, Bergman S, Arvidsson B. Patients' perceptions of drug information given by a rheumatology nurse: a phenomenographic study. *Musculoskeletal care*. 2010;8(1):36-45.
98. Alfaro N, Lazaro P, Gabriele G, Garcia-Vicuna R, Jover JA, Sevilla J. Perceptions, attitudes and experiences of family caregivers of patients with musculoskeletal diseases: a qualitative approach. *Reumatologia clinica*. 2013;9(6):334-9.
99. Backman CL, Smith Ldel F, Smith S, Montie PL, Suto M. Experiences of mothers living with inflammatory arthritis. *Arthritis and rheumatism*. 2007;57(3):381-8.
100. Betteridge N, Boehncke WH, Bundy C, Gossec L, Gratacos J, Augustin M. Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2015.
101. Madsen M, Jensen KV, Esbensen BA. Men's experiences of living with ankylosing spondylitis: a qualitative study. *Musculoskeletal care*. 2015;13(1):31-41.
102. Martindale J, Goodacre L. The journey to diagnosis in AS/axial SpA: the impact of delay. *Musculoskeletal care*. 2014;12(4):221-31.
103. Pelaez-Ballestas I, Perez-Taylor R, Aceves-Avila JF, Burgos-Vargas R. 'Not-belonging': illness narratives of Mexican patients with ankylosing spondylitis. *Medical anthropology*. 2013;32(5):487-500.
104. Pelaez-Ballestas I, Romero-Mendoza M, Burgos-Vargas R. If three of my brothers have ankylosing spondylitis, why does the doctor say it is not necessarily hereditary? The meaning of risk in multiplex case families with ankylosing spondylitis. *Chronic illness*. 2015.

05. Davies H, Brophy S, Dennis M, Cooksey R, Irvine E, Siebert S. Patient perspectives of managing fatigue in Ankylosing Spondylitis, and views on potential interventions: a qualitative study. *BMC musculoskeletal disorders*. 2013;14:163.
06. Eilertsen G, Ormstad H, Kirkevold M, Mengshoel AM, Soderberg S, Olsson M. Similarities and differences in the experience of fatigue among people living with fibromyalgia, multiple sclerosis, ankylosing spondylitis and stroke. *J Clin Nurs*. 2015;24(13-14):2023-34.
07. Lacaille D, White MA, Backman CL, Gignac MA. Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective. *Arthritis and rheumatism*. 2007;57(7):1269-79.
08. Mortada M, Abdul-Sattar A, Gossec L. Fatigue in Egyptian patients with rheumatic diseases: a qualitative study. *Health and quality of life outcomes*. 2015;13:134.
09. Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The patient experience with fatigue and content validity of a measure to assess fatigue severity: qualitative research in patients with ankylosing spondylitis (AS). *Health and quality of life outcomes*. 2013;11:192.
10. Stamm T, Hieblinger R, Bostrom C, Mihai C, Birrell F, Thorstensson C, et al. Similar problem in the activities of daily living but different experience: a qualitative analysis in six rheumatic conditions and eight European countries. *Musculoskeletal care*. 2014;12(1):22-33.
11. Uttjek M, Nygren L, Stenberg B, Dufaker M. Marked by visibility of psoriasis in everyday life. *Qualitative health research*. 2007;17(3):364-72.
12. Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. *Health and quality of life outcomes*. 2009;7:62.
13. McArthur MA, Birt L, Goodacre L. "Better but not best": a qualitative exploration of the experiences of occupational gain for people with inflammatory arthritis receiving anti-TNFalpha treatment. *Disability and rehabilitation*. 2015;37(10):854-63.
14. Pasma A, van 't Spijker A, Luime JJ, Walter MJ, Busschbach JJ, Hazes JM. Facilitators and barriers to adherence in the initiation phase of Disease-modifying Antirheumatic Drug (DMARD) use in patients with arthritis who recently started their first DMARD treatment. *The Journal of rheumatology*. 2015;42(3):379-85.
15. Mengshoel AM. Living with a fluctuating illness of ankylosing spondylitis: a qualitative study. *Arthritis and rheumatism*. 2008;59(10):1439-44.
16. Moverley AR, Vinall-Collier KA, Helliwell PS. It's not just the joints, it's the whole thing: qualitative analysis of patients' experience of flare in psoriatic arthritis. *Rheumatology (Oxford, England)*. 2015;54(8):1448-53.
17. Gronning K, Lomundal B, Koksvik HS, Steinsbekk A. Coping with arthritis is experienced as a dynamic balancing process. A qualitative study. *Clinical rheumatology*. 2011;30(11):1425-32.
18. Barlow JH, Cullen LA, Foster NE, Harrison K, Wade M. Does arthritis influence perceived ability to fulfill a parenting role? Perceptions of mothers, fathers and grandparents. *Patient education and counseling*. 1999;37(2):141-51.
19. Aguiar R, Ambrosio C, Cunha I, Barcelos A. Sexuality in spondyloarthritis—the impact of the disease. *Acta reumatologica portuguesa*. 2014;39(2):152-7.
20. Cakar E, Dincer U, Kiralp MZ, Taskaynatan MA, Yasar E, Bayman EO, et al. Sexual problems in male ankylosing spondylitis patients: relationship with functionality, disease activity, quality of life, and emotional status. *Clinical rheumatology*. 2007;26(10):1607-13.
21. Haugli L, Strand E, Finset A. How do patients with rheumatic disease experience their relationship with their doctors? A qualitative study of experiences of stress and support in the doctor-patient relationship. *Patient education and counseling*. 2004;52(2):169-74.

22. (CEBM) OCfE-bM. Centre for Evidence Based Medicine – Levels of Evidence (March 2009). Disponible en:<http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>.